title: Clinical experience with autologous M2 macrophages in children with severe cerebral palsy.
abstract: Stem cell-based therapy is considered to be a new approach for the treatment of cerebral palsy (CP). Given the potent anti-inflammatory activity and high regenerative potential of M2 macrophages, these cells may be an alternative source for cell transplantation. To evaluate the safety and efficacy of autologous M2 macrophages, we conducted a pilot clinical trial in 21 children with severe CP. The primary outcome measure was safety, which included assessment of mortality of any cause, immediate adverse reactions, and serious adverse effects and comorbidities during 5-year follow-up. The secondary outcome measure was functional improvement in Gross Motor Function Measure (66-item GMFM) test, Peabody Developmental Motor Scale-Fine Motor (PDMS-FM) test, Ashworth scale, MRC scale, and an easy-to-understand questionnaire for evaluation of cognitive functions in our modification. Intradural injection of M2 cells (in mean dose of 0.8 × 10(6)/kg) into the lumbar spinal area did not induce any serious adverse events. No cases of mortality, psychomotor worsening, exacerbation of seizures, and long-term comorbidities, including tumors, were observed during a 5-year follow-up. After 3 months, GMFM score increased from 13.7 ± 7.8 to 58.6 ± 14.6, PDMS-FM score improved from 0.76 ± 0.42 to 5.05 ± 0.97, and the Ashworth score decreased from 3.8 ± 0.21 to 3.3 ± 0.24. Along with gross and fine motor function enhancement, an improvement of cognitive activity (from 1.62 ± 0.41 to 4.05 ± 0.64, according to questionnaire assessment) and reduction of seizure syndrome were registered as well. The neurological improvements did not diminish during the 5-year follow-up period. The data obtained suggest that cell therapy based on M2 macrophages is safe, does not induce early adverse effects and long-term comorbidities, and is accompanied with a significant improvement of motor and cognitive activities in severe CP patients. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation.
authors.affiliation: Laboratory of Cellular Immunotherapy, Institute of Clinical Immunology of Russian Academy on Medical Sciences, Siberian Branch, Novosibirsk, Russia.
authors.forename: Elena R
authors.initials: ER
authors.lastname: Chernykh
authors.forename: Marina Yu
authors.initials: MY
authors.lastname: Kafanova
authors.forename: Ekaterina Ya
authors.initials: EY
authors.lastname: Shevela
authors.forename: Sergei I
authors.initials: SI
authors.lastname: Sirota
authors.forename: Elena I
authors.initials: EI
authors.lastname: Adonina
authors.forename: Lyudmila V
authors.initials: LV
authors.lastname: Sakhno
authors.forename: Alexander A
authors.initials: AA
authors.lastname: Ostanin
authors.forename: Vladimir V
authors.initials: VV
authors.lastname: Kozlov
mesh_terms: D002547:Cerebral Palsy / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D008264:Macrophages / Q000637:transplantation*; D008297:Male; D009043:Motor Activity; D020127:Recovery of Function; D013997:Time Factors; D014182:Transplantation, Autologous
chemical_list: D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins